Guggenheim downgraded Arcturus Therapeutics (ARCT) to Neutral from Buy.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Arcturus Therapeutics Announces Phase 2 Trial Results
- Arcturus Therapeutics announces interim results from ARCT-032 trial
- Citi places ‘upside 90-day catalyst watch’ on Arcturus Therapeutics
- Arcturus Therapeutics Partners on New COVID-19 Vaccine Launch
- Cathie Wood Scales Back Roku and Roblox Stakes, Boosts Arcturus Holding